Soleno Therapeutics, Inc.
SLNO
$52.95
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 3.13% | 38.95% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 3.13% | 38.95% | |||
| Cost of Revenue | 38.82% | -24.36% | |||
| Gross Profit | 2.79% | 40.06% | |||
| SG&A Expenses | 23.22% | 21.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.50% | 18.48% | |||
| Operating Income | -21.44% | 77.96% | |||
| Income Before Tax | -19.48% | 66.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -27.63% | 66.68% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -27.63% | 66.68% | |||
| EBIT | -21.44% | 77.96% | |||
| EBITDA | -21.16% | 76.31% | |||
| EPS Basic | -25.41% | 65.56% | |||
| Normalized Basic EPS | -18.26% | 66.49% | |||
| EPS Diluted | -25.34% | 68.15% | |||
| Normalized Diluted EPS | -18.03% | 67.85% | |||
| Average Basic Shares Outstanding | -2.04% | -0.29% | |||
| Average Diluted Shares Outstanding | -2.33% | -1.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||